



Published in final edited form as:

J Mol Biol. 2009 May 8; 388(3): 644–658. doi:10.1016/j.jmb.2009.03.037.

ELUCIDATING THE INHIBITION MECHANISM OF HIV-1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS THROUGH MULTI-COPY MOLECULAR DYNAMICS SIMULATIONS

Anthony Ivetac^{1,*} and J. Andrew McCammon^{1,2,3,4}

¹ Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0365, United States

² Center for Theoretical Biological Physics, University of California San Diego, La Jolla, CA 92093-0365, United States

³ Howard Hughes Medical Institute, University of California San Diego, La Jolla, CA 92093-0365, United States

⁴ Department of Pharmacology, University of California San Diego, La Jolla, CA 92093-0365, United States

Abstract

HIV-1 reverse transcriptase (RT) inhibition is a major focus of current anti-AIDS drug discovery and development programs, comprising 17 of the 31 FDA-approved compounds. The emergence of the non-nucleoside RT inhibitor (NNRTI) class of compounds provides a highly specific and structurally diverse set of drugs, which act non-competitively to perturb normal RT function. Despite a relatively rich set of crystallographic data of RT in various states, details of the allosteric modulation of RT dynamics by NNRTIs are lacking. Capturing this inhibitory mechanism could fuel the design of more effective inhibitors at the NNRTI site and also drive the identification of novel allosteric sites. To address this, we have performed multi-copy molecular dynamics (MD) simulations of RT in the presence and absence of the NNRTI nevirapine (cumulative total simulation time 360 ns). By comparing the collective motions of both the MD and crystallographic structures, we demonstrate that the chief effect of NNRTIs is to constrain a key rigid-body motion between the “fingers” and “thumb” subdomains of the p66 subunit. We show that the NNRTI binding pocket (NNIBP) is proximal to the hinge points for this essential motion and NNRTIs therefore act as “molecular wedges”, sterically blocking the full range of motion. To explain how this impaired movement might result in the experimentally observed loss of polymerase activity, we show that the motion influences the geometry of key catalytic residues on opposite faces of the NNIBP. From a methodological point of view, our results suggest that the multi-copy MD simulation approach is very useful when studying proteins which perform such large conformational changes.

Introduction

Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) currently represents the fourth leading cause of death worldwide and has been projected to

*to whom correspondence should be addressed at: e-mail: aivetac@mccammon.ucsd.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

become the third leading cause by 2030¹. The gravity of this infectious disease has led to the development and approval of a range of pharmaceutical compounds, which interfere with various stages of the HIV-1 retroviral life cycle². Due to the drug resistance mechanisms of retroviruses, HIV chemotherapeutic regimens typically administer a combination of these compounds, spanning different classes of drugs and often different targets³. Currently, the most popular drug target is the HIV-1 reverse transcriptase (RT) enzyme, which is required for the conversion of retroviral RNA into DNA and is thus vital for viral replication⁴. Existing RT inhibitors can be divided into two classes: nucleoside RT inhibitors (NRTIs), which mimic the endogenous substrates and bind competitively at a catalytic site, and non-nucleoside RT inhibitors (NNRTIs), which bind non-competitively at an allosteric site^{5, 6}. NNRTIs are attractive by virtue of their high specificity for HIV-1 RT, whereas NRTIs cause severe side effects by also inhibiting human DNA polymerases⁷. Furthermore, NNRTIs are more amenable to structure-based drug design efforts as they do not require prior metabolic activation and can adopt a more diverse range of structures⁸. However, NNRTIs are afflicted with the same vulnerability to drug-resistance mutations which affects other retroviral drugs and which is manifested in a highly variant binding site⁹. To date, four NNRTIs have been approved for clinical use by the Food and Drug Administration (FDA): nevirapine, delavirdine, efavirenz and, most recently, etravirine^{10, 11}. Etravirine (and rilpivirine, which is currently undergoing Phase III clinical trials) are members of the recent diarylpyrimidine (DAPY) group of NNRTIs, which has generated significant excitement through its tolerance of RT mutations which incapacitate previous NNRTIs^{12, 13}. Crystallography has shown that the DAPY chemical structure permits the conformational flexibility to bind in multiple “poses” and thus elude mutations which impair the binding of other, more rigid inhibitors¹⁴.

HIV-1 RT catalyzes the transcription of the single-stranded RNA viral genome into a double-stranded DNA form, which can be integrated into the human genome as the provirus. A wealth of crystallographic studies has been performed on RT, yielding ~60 high-resolution structures of the protein in a variety of states (as reviewed in¹⁵ and documented in¹⁶). These include the “apo” form (no substrate and no inhibitor – e.g. PDB code 1DLO¹⁷ and 1HMV¹⁸), substrate-bound forms (binary complexes of protein with nucleic acid substrate and the ternary complex of protein with nucleic acid and nucleoside triphosphate – e.g. PDB codes 2HMI¹⁹ and 1RTD²⁰) and NNRTI-bound forms (co-crystallized NNRTIs, but no substrate – e.g. PDB codes 1BQM²¹ and 1EP4²²). RT is a 1,000 amino-acid heterodimer of p66 and p51 subunits, which are each composed of “fingers”, “thumb”, “palm” and “connection” subdomains. The spatial arrangement of these subdomains is very different between the two subunits and it is thought that the p51 subunit mainly plays a structural role, with polymerization occurring at the p66 subunit¹⁵. Together, the fingers, palm and thumb subdomains of p66 resemble a right hand and form a “clamp” which holds the double-stranded template-primer in position. Notably, the palm subdomain contains the “catalytic triad” of three aspartate residues (Asp110, Asp185 and Asp186), which are essential for the addition of nucleotide to the growing primer strand and the so-called “primer grip”, which is thought to be required for correct positioning of the 3' end of the primer²³. The p66 subunit contains an additional subdomain, known as the RNase H (RNH) domain, which is responsible for the other enzymatic activity of the protein - degradation of the RNA strand during polymerization.

The allosteric NNRTI binding pocket (NNIBP) is located approximately 10 Å away from the p66 polymerase active site and is not present in either the apo or substrate-bound crystal structures. In these cases, the NNIBP is occluded, predominantly by the aromatic sidechains of Tyr181 and Tyr188, which must undergo large torsional rotations in order to swing out of the pocket to accommodate NNRTIs²⁴. Although the co-crystallized NNRTIs represent diverse structures and show differences in binding modes within the NNIBP, they all elicit similar structural rearrangements with respect to the NNRTI-free forms. The most consistent, and short-range, NNRTI-induced effect is a relative movement of two β-sheets which lie on

opposite sides of the NNIBP^{9, 25, 26}. A more long-range effect is a change in the dimensions of the nucleic acid clamp, formed by the space between the fingers, palm and thumb subdomains. While this cleft is essentially occluded in the apo form, it opens to accommodate nucleic acid in the substrate-bound form and opens even further in the NNRTI-bound form, despite the absence of nucleic acid^{18, 20}.

Despite these insightful comparative observations of crystallographic “snapshots” of RT, the molecular mechanism by which NNRTIs inhibit reverse transcription is still unknown. However, various models have been postulated, based on structural and biochemical data. Coined “molecular arthritis”, the first scheme suggests that NNRTIs lock the enzyme in an inactive conformation, by immobilizing the thumb subdomain²⁷. Biochemical evidence has since crucially revealed that NNRTIs do not affect the ability of RT to form a ternary complex with nucleic acid and nucleoside triphosphate, but specifically inhibit the chemical step of nucleotide incorporation into the primer strand^{28,29}. This has prompted and supported inhibition models involving observed distortions of residues local to the polymerase active site, namely the primer grip and catalytic triad. The former proposes that the shift of the primer grip causes incorrect placement of the 3' primer end relative to the catalytic site and consequently a catalytically incompetent constellation of these key protein and nucleic acid atoms²³. The latter proposes a similar fate, although more directly, through movement of the natural position of the catalytic triad²⁶. More recently, fluorescence experiments have suggested that NNRTI-induced loosening of the fingers-thumb grip (as seen in the crystal structures) may cause RT to slide away from the 3' primer end and thus prevent polymerization³⁰.

In the light of such predictions, various computational methods have been employed to explore aspects of the conformational dynamics of RT which cannot be addressed experimentally. Short timescale molecular dynamics (MD) simulations of RT have given insights to the structural flexibility of the enzyme in various starting conformations and with various ligands. Rapid collapse of the thumb subdomain from an “open” to a “closed” conformation has been presented via 1 nanosecond (ns) implicit solvent simulations³¹. 1.1 ns explicit solvent MD simulations demonstrated increased RT flexibility in the presence of double-stranded DNA, compared to the apo form³². A non-equilibrium MD study (involving simulations 3 ns in length and modelling a subset of the protein residues) revealed details of NNRTI binding/unbinding and supported the “molecular arthritis” model of inhibition, together with NNRTI-induced expansion of the nucleic acid clamp³³. Most recently, 2.5 ns explicit solvent MD simulations of RT in NNRTI-bound and NNRTI-free conformations also supported the “molecular arthritis” model and found that resistance mutations were able to partially reverse this effect³⁴. A coarse-grained modeling method has been adopted by Bahar and co-workers, who have used elastic networks to model the collective dynamics of RT in different conformations^{35, 36, 37}. Their findings have indicated the relative flexibility and cooperativity of the RT subdomains and most interestingly revealed hinge regions which may be allosteric inhibitor targets. However, different versions of the network model have yielded conflicting results on the effect of NNRTIs on the motion of the thumb subdomain (the gaussian network model indicated a “severe repression”³⁵, while the anisotropic network model showed “marginal” effects for the same NNRTI³⁷). Moreover, NNRTI-induced effects were deduced from radically different structures, probably because the network model is too coarse to detect the effect of a drug on the same structure (a drug molecule is modelled as a single network node).

In this work, we present a multi-copy MD simulation study of RT, comparing protein conformational dynamics in the presence and absence of the FDA-approved NNRTI nevirapine. Our chief aim is to detect NNRTI-induced changes in the native dynamics of RT and thus clarify the inhibition mechanism of NNRTIs, in the light of existing experimental and computational findings. Our motivation is that a better understanding of how NNRTIs abolish enzymatic function will enhance future NNRTI drug design and help identify novel allosteric

sites near other catalytic regions critical for HIV replication. Three simulation systems have been studied: i) Apo RT with the nucleic acid binding cleft closed (APO1); ii) Apo RT with the nucleic acid binding cleft open (APO2); iii) Nevirapine-bound RT with the nucleic acid binding cleft open (NNRTI-bound, NNB) – see Figure 1 for summary. Principal component analysis (PCA) is used to demonstrate the debilitating effect of nevirapine on a key global motion of RT, through steric block of a hinge region. This motion influences the geometry of key substrate-binding and catalytic residues and thus strongly supports the proposed “primer grip” and “catalytic triad” inhibition models. This study is distinguished from previous RT simulation work through a dramatic increase in simulation time, thanks to continuing advances in computer hardware. A series of four 30 ns trajectories are carried out for each of the three systems (cumulative total of 360 ns) – each an order of magnitude longer than the longest previous trajectory of 3 ns³³. The combination of significantly longer trajectories and the multi-copy approach³⁸ allows for a more exhaustive conformational sampling of RT, compared to individual, shorter trajectories. Tackling the issue of incomplete sampling is particularly germane in this study, considering the magnitude of the structural variation observed crystallographically and the large size of the protein.

Results and Discussion

Crystallographic Ensemble

Before investigating the conformational dynamics of RT from the MD simulations, it is important to establish the structural changes which have already been captured via x-ray crystallography, as an experimental reference. To this end, we compiled a set of 13 x-ray structures which represent the different crystal forms ($1 \times$ apo, $2 \times$ substrate bound and $10 \times$ NNRTI-bound) and consequently the majority of the conformational variation (see Figure 2 for details). Although there are ~60 crystal structures available, the bulk of these are NNRTI-bound and mutant forms which only contain subtle, local differences from each other and therefore do not significantly affect the global variance of the protein. The “crystallographic ensemble” (Figure 2A) has been subjected to PCA in order to examine the conformational differences, as has been performed previously on other proteins for which substantial crystallographic data exists (e.g. ^{39, 40}). The first two eigenvectors from the PCA capture 86% of the variance of the entire crystallographic ensemble and thus represent large-scale collective motions, with subsequent eigenvectors capturing significantly smaller fluctuations. It is thought that the large displacements seen in the first few eigenvectors of such analyses represent functionally important global movements (the so-called “essential dynamics”), while lower order eigenvectors are smaller, localized fluctuations that do not influence function⁴¹. Accordingly, PCA studies focus on these dominant motions and Figure 2B shows the projection of each member of the crystallographic ensemble onto the plane defined by the top two eigenvectors. This plot illustrates the relationship between the crystal structures within this 2-dimensional “essential subspace” and one can define clusters which correlate with the ligation state of the protein. As expected, the greatest separation is seen between the apo and ligand-bound forms, which contain closed and open forms of the nucleic acid binding cleft, respectively. A more subtle shift is seen between the substrate-bound and NNRTI-bound clusters, as a result of smaller changes in the fingers and thumb subdomains.

To characterize the collective motions represented by these dominant eigenvectors, interpolations between the extreme projections of the crystal structures have been shown in Figures 2C and 2D. The bulk of the displacement is seen in the polymerase region in both cases and eigenvector 1 represents a concerted opening and closing event at the nucleic acid binding cleft (Figure 2C). The anti-correlated, rigid-body motions of the fingers and thumb subdomains modulate the size of the cleft and make dramatic changes in position, representing 77% of the variance in the crystallographic ensemble. The functional significance of this motion probably

lies in its role in the clamping and release of the nucleic acid substrate, which happens at multiple stages during reverse transcription. Observing the projections onto this mode along the x-axis in Figure 2B, the apo form represents the most closed state of the cleft, in the absence of nucleic acid (fingers and thumb subdomains contacting each other). Widening of the fingers-thumb distance in the substrate-bound forms represents the accommodation of nucleic acid into the cleft, analogously to the “venus flytrap” models of substrate binding/recognition⁴². Further expansion is seen in all of the NNRTI-bound structures (through additional movement of the fingers), which may be linked to the inhibition mechanism and stabilizes a “hyper-open” form of the empty cleft. Eigenvector 2 represents a significantly smaller displacement of atoms, representing 9% of the variance of the crystallographic ensemble (Figure 2D). This motion involves orthogonal movements of the fingers and thumb subdomains, with the thumb moving outwards in concert with the fingers moving towards the center of the protein. While the functional significance of this motion is less clear, it is possible that this flexibility is required for the polymerase region to translocate along the growing nucleic acid, after successive nucleotide additions. Indeed, a role for motion of the thumb subdomain has previously been proposed in a model for the translocation mechanism⁴³.

Simulation Dynamics

The conformational drift of the RT structure throughout the MD simulations has been measured in terms of the root mean-square deviation (RMSD) with respect to the starting structure (Figure 3). Plotting the RMSD of all C α atoms as a function of time for the four simulation copies reveals relatively large changes in structure, indicative of significant domain movements (Figure 3A). After an initial sharp rise in each simulation (as the crystal coordinates adjust to simulation conditions), RMSDs vary within a window of between 3 Å – 6.5 Å and in some cases appear to stabilize. However, in most cases the structural drift is continual, the RMSDs not reaching the “plateau” characteristic of less mobile structures. Notably, even the largest RMSDs are contained within an upper-bound set by the RMSD between the two starting structures (7 Å). This suggests that such large drifts are reasonable, given the structural plasticity observed experimentally. Such values have not been attained in previous shorter MD simulations of RT, where structures have typically not exceeded 3.5 Å RMSD from the starting structure and appear to stabilize (e.g.^{32, 34}). Interestingly, if RMSD analysis from our simulations is restricted to such timescales (i.e. the first 3 ns), the resulting RMSDs are substantially lower and show much softer fluctuations reminiscent of stabilization (data not shown). We therefore propose that the longer timescales attained in this study allow for greater structural changes through enhanced conformational sampling. Another striking feature of the RMSD plots is the difference between individual copies of the same simulation system, which suggests that the multi-copy approach has been successful in generating more conformational variation than a single trajectory. Comparing the structural drift between apo and NNRTI-bound forms across all copies does not yield any significant differences, although the mean RMSD is slightly lower for the NNRTI-bound simulations. This comparison highlights another disadvantage of running single trajectories – if one were to simply analyze the third copy of each system, for example, one might conclude that the APO1 system is substantially less stable than the APO2 and NNB systems. In fact, this difference is diluted when we consider the other three copies and consequently obtain better statistics.

Which RT domains and motions are responsible for the large drifts seen in the RMSD analysis? Figure 3B shows the backbone traces of the three simulation ensembles after least-squares fitting, with notable conformational changes occurring at the nucleic acid binding cleft. Large fluctuations of the fingers and thumb subdomains are seen from both the initial closed conformation in APO1 and the open confirmation in APO2. However, there is a noticeable reduction in the opposing movement of the fingers and thumb in the NNB ensemble, which is clearly identified by the visibility of the palm subdomain (largely occluded in APO2). While

there is contact between the tips of the fingers and thumb subdomains in APO2, these regions do not approach each other by the same extent in the NNB ensemble. These qualitative results suggest that modulation of the opening and closing of the nucleic acid binding cleft is deficient with nevirapine bound.

A quantitative analysis of the flexibility of the different subdomains of RT is performed through the root mean-square fluctuation (RMSF) of $C\alpha$ atoms, with respect to their time-averaged positions (Figure 4). Plotting the RMSF as a function of residue number (Figure 4A) reveals greatest movements from the fingers and thumb subdomains of the p66 subunit, as observed above. A smaller degree of flexibility is seen at the RNH domain, while the p51 subunit generally shows much lower values than p66, consistent with its structural role in the heterodimer. The two sharp peaks in the latter half of the plot belong to the highly mobile C-terminus of p66 and a very flexible solvent-exposed loop in the center of p51. Comparing the RMSFs of the different simulations reveals very similar profiles and we do not observe the ligation state dependent differences seen in previous studies, whereby NNRTI binding reduced RT flexibility across all residues³⁴. However, a pronounced local effect of NNRTI binding is observed at the tip of the p66 thumb subdomain (indicated by the dotted box in Figure 4A). The APO2 simulations (red) show a marked increase in thumb flexibility compared to the NNB simulations (blue). In contrast, the APO1 simulations show identical p66 thumb flexibility to the NNB simulations, likely reflecting the different starting conformations of the cleft. The RMSF results are visualized in the context of the 3-dimensional starting structure of each system in Figure 4B. These images depict a relatively immobile core at the center of the heterodimer, with all flexibility occurring around the periphery of the structure. Together with the snapshots seen in Figure 3B, it is clear that the outermost region of the p66 thumb domain is more mobile in the absence of nevirapine, specifically making stronger moves towards the fingers.

Essential Dynamics Analysis

The results above suggest that nevirapine may exert a local effect on the flexibility of residues in the polymerase region. However, considering the high dimensionality of proteins, it is particularly difficult to identify which motions are of biological importance. In order to filter out functionally relevant collective motions (the likely targets of an inhibition mechanism) from local “noise”, we have performed PCA to uncover the essential dynamics of each simulation ensemble⁴¹. This allows us to characterize the essential motions from each simulation and compare them both with each other and with the motions from the crystallographic ensemble (as seen in Figure 2). Such a technique has proved valuable in identifying ligand-induced effects on functional dynamics of the apo-enzyme in other work (e.g.^{44, 45, 46}).

Figure 5 shows the cumulative proportion of the total variance (i.e. total mean-square fluctuation) which is captured by each eigenvector from the PCA of the MD trajectories. This plot clearly illustrates that the bulk of the protein dynamics are described in a relatively small number of eigenvectors, which represent collective movements of atoms. From the inset, the first eigenvector in each system dominates, representing as much as 58% of all fluctuations, while successive degrees of freedom capture significantly smaller modes. While this trend is seen in all systems, it is clear that the total proportion of variance captured by the first few eigenvectors is consistently lower for the NNB system compared to both the APO1 and APO2 systems. This result suggests that nevirapine binding affects the essential dynamics of RT, possibly by dampening key motions (which have stronger displacements in the apo form).

The most significant result of the analysis was obtained when we compared the essential motions captured by the first few eigenvectors, by initially viewing animations of the extreme projections of the trajectories. The motion represented by eigenvector 1 showed dramatic

differences around the polymerase region when comparing the apo and NNRTI-bound simulations (Figure 6). In the APO1 and APO2 simulations, eigenvector 1 is characterized by an opening/closing of the fingers and thumb subdomains which is very similar to that seen in the crystallographic ensemble. Views of the motion from both the top and the side of the protein reveal qualitative similarities which are supported by high inner product values of 0.71 and 0.77, respectively. The amplitude of the motion is slightly stronger in the APO2 system, largely due to the greater motion of the thumb subdomain and likely because of the initial open configuration of the cleft. In sharp contrast, eigenvector 1 of the NNB simulations shows a very different motion, with the fingers and thumb subdomains making movements roughly orthogonal to those seen in the apo simulations. As a result, there is no change in the size of the cleft, as no moves are made towards the center of the cleft, and the dissimilarity of the motion is seen in the low inner product value of 0.26. This result explains the different variance of the fingers and thumb subdomains seen in the trajectory snapshots in Figure 3B – i.e. opening and closing of the cleft is not the dominant mode of motion in the NNB system. In fact, eigenvector 1 from the NNB system actually bears resemblance to eigenvector 2 from the crystallographic ensemble (as seen in Figure 2D) and this is reflected in the high inner product value of 0.7 between these two motions. Furthermore, motions more similar to the characteristic opening/closing motion of the cleft are seen in less dominant modes of the NNB system, with eigenvectors 2 and 6 having higher inner products of 0.57 and 0.66, respectively. By definition, these lower order eigenvectors represent significantly less fluctuation than the first eigenvector (combined, eigenvectors 2 and 6 represent 17% of the total variance in the NNB system, compared to 42% for eigenvector 1). Therefore our results show that opening and closing motions of the cleft are attenuated in the presence of nevirapine, such that they are relegated to less dominant modes in the PCA results.

In order to directly compare regions sampled by the essential motions from the trajectories, we have projected the simulation ensembles onto the plane defined by the top two eigenvectors of the crystallographic ensemble (for example, as seen in ⁴⁷). As expected, notable differences are seen in the fluctuation of the systems along eigenvector 1 (Figure 7). The APO1 system largely occupies the closed cleft region, but also contains a cluster of states in a more open conformation, similar to that seen in the substrate-bound crystal forms. Similarly, the APO2 system explores both the open region common to NNRTI bound structures and a second more closed conformation. Interestingly, the APO1 and APO2 systems show considerable overlap in the cluster of conformations which is furthest from their starting structures. This “semi-open” state of the cleft marks the midpoint between the two starting structures and could represent a low energy conformation which initially binds the nucleic acid substrate. In contrast, the NNB system is largely confined to the NNRTI-bound region of the plane, which is a subset of approximately half the region sampled by the APO2 system. Unlike the APO2 system, in the cleft closure events that do occur, none are strong enough to overlap with either the substrate-bound structures or the APO1 structures. For eigenvector 2, we observe similar ranges sampled by all systems, supporting the earlier observation that this motion is unrestricted by nevirapine binding.

Another method which has been used to detect inter-simulation differences is the “combined essential dynamics” approach, whereby PCA is performed on the concatenated MD trajectories ^{45, 48}. The individual trajectories are then projected onto the resulting eigenvectors to identify which regions are sampled. Thus, the reference set of essential dynamics is obtained from MD simulation rather than crystallography. We repeated the 2D projection shown in Figure 7 using this combined approach and produced a plot with striking similarity, suggesting high correlation between the principal components from the crystallographic and combined 360 ns MD ensemble (see Supplementary Info). Indeed, the inner products of the top two eigenvectors from the two different sources of structures are very high at 0.93 and 0.8, respectively. Interestingly, these values are higher for the combined 360 ns MD ensemble than the individual

120 ns sub-ensembles, an effect which has been observed previously when comparing crystallographic and MD principal components of the T4 lysozyme⁴⁷. We note that the inner products for eigenvectors 3 and greater are considerably smaller; however these motions combined represent only 14% and 25% of the fluctuations of the crystallographic and MD ensembles, respectively. This result serves to validate the MD method in its reproduction of the experimentally observed large-scale motions of RT.

The PCA results suggest that nevirapine binding is associated with a defective opposing motion of the p66 fingers and thumb subdomains, which dominates the crystallographic and apo simulation ensembles. We validated this by measuring the distance between the center-of-mass of the thumb and fingers subdomains as a function of time (Figure 8). The distribution of inter-domain distances correlates very well with the densities of the regions sampled by each system along eigenvector 1 and shows the overlap of the apo systems (Figure 8A). Both apo systems are able to make opening/closing motions, which allows them to attain inter-domain distances similar to those seen in the substrate-bound crystal structures. The cleft of the NNB system is unable to close to the same extent as the APO2 system and thus cannot reach the dimensions of the substrate bound structures. This suggests that incomplete closure of the cleft may preclude the formation of a catalytically active complex with nucleic acid. Analyzing the distances as a function of time, we can clearly see the value of running multi-copy simulations (Figure 8B). For the APO1 simulation, the fingers and thumb retain their initial closed conformation for the first two copies, but open up in the third and fourth copies. In the APO2 simulations, a pronounced closing event occurs in the fourth copy, with fluctuations that attain the cleft size of the substrate-bound crystal structure in the first and second copy. In the NNB simulations, the distance fluctuates around its initial value, never reaching the cleft size of the substrate-bound crystal structure in any copies. These measurements support our observation that nevirapine weakens the inter-domain motion of the fingers and thumb subdomains, locking them in an extended conformation. Furthermore, they show that multi-copy simulations of this timescale are necessary to observe such large conformational changes, which may not be captured otherwise.

NNRTIs Act As Molecular Wedges

How does nevirapine exert an inhibitory effect on the dominant subdomain motion of the RT polymerase region? Further inspection of this motion was performed using HingeFind⁴⁹, which allowed us to define the two groups of residues which make opposing rigid body movements along this mode. The first group is composed of the fingers subdomain and neighbouring residues of the palm subdomain (colored blue in Figure 9A), while the second group is composed of the thumb subdomain and neighbouring residues from the palm subdomain (colored red in Figure 9A). By using the extreme projections on this motion, we were able to calculate the hinge axis and pivot-point for the rigid-body motion of each group (green spheres in Figure 9A). Importantly, the pivot for each motion is located adjacent to the NNIBP, and thus NNRTIs bind at the hinge region for both groups. Because full motion along this mode requires the opposing movement of residues which line the NNIBP, the presence of a NNRTI effectively “wedges” this hinge region through steric block, and thus precludes full closure of the two groups (Figure 9B). We therefore propose that NNRTIs block a key hinge region in the polymerase region, which normally permits the full opposing motion of the fingers and thumb subdomains (and associated palm residues). Previous computational studies of RT, using elastic network models, have also implicated the NNIBP region in a hinge-bending function^{35, 37}. A very similar ligand-induced effect is seen in a previous simulation study of apo and calcium-bound annexin V, whereby calcium dampens a key hinge-bending motion and favors more open hinge conformations⁴⁴. Interestingly, recent structures of the bacterial RNA polymerase (RNAP) reveal a very similar mechanism of inhibition by antibacterial compounds⁵⁰. These drugs bind at a hydrophobic site analogous to the NNIBP of RT and are

thought to inhibit the enzyme by blocking a hinge that modulates the size of a nucleic acid binding cleft. Therefore, this allosteric hinge blocking mechanism may be universal to related nucleic acid binding proteins and could be a useful target for therapies targeting novel enzymes.

How does the defective hinge bending motion of RT preclude the chemical step of DNA polymerization? In the immediate vicinity of the hinge region are two β -sheet structures of the palm subdomain which lie on either side of the NNIBP and effectively “sandwich” the NNRTI. The first is composed of β -strands 12–14 (associated with the thumb subdomain motion) and the second is composed of β -strands 6, 9 and 10 (associated with the fingers subdomain motion). The hinge-bending motion causes the two sheets to “shear” against each other (Figure 9C), thus bringing the sheets closer together when the hinge closes and further apart when the hinge opens. The upper section of these structures each houses crucial residues for polymerization: the first sheet includes the primer grip and, on the opposite side, the second sheet includes the catalytic triad (Figure 9D). Restriction of the hinge motion by a NNRTI would therefore constrain the constellation of the primer grip, catalytic triad and bound substrate, causing the formation of an unproductive ternary complex. A second possibility is that defective closure of the hinge and cleft reduces the number of contacts between RT and its nucleic acid substrate, causing the 3' primer end of the substrate to prematurely move away from the polymerase active site. This suggestion is based on recent work by Liu and coworkers, who propose that the loosening of the RT cleft around its nucleic acid substrate is part of the natural cycle of reverse transcription and causes the enzyme to slide away from the 3' primer end when transcription is complete³⁰.

Conclusions

In this work, we have performed all-atom MD simulations of the HIV-1 RT enzyme, in both the presence and absence of the NNRTI nevirapine. The principal aim of this study was to identify how the binding of a NNRTI at an allosteric site affects the conformational dynamics of RT such that it inhibits DNA polymerization. We have employed PCA as a tool to extract the essential dynamics from both experimental (crystallographic) and theoretical (MD) ensembles of RT structures, focussing on the catalytic p66 subunit. Comparison of the dominant modes of motion from each source revealed that while NNRTI-free simulations reproduced very similar movements to those of the crystallographic dataset, those of the NNRTI-bound simulations were quite distinct. Most significantly, the NNRTI-bound enzyme is severely constrained in its sampling of the dominant mode of fluctuation, which is characterized by the opening/closing motion of the fingers and thumb subdomains. We have shown that NNRTIs bind close to the hinge region for this motion and “wedge” between the subdomains, thus restricting the range of the hinge-bending mechanism. This result is supported by previous computational studies, which predicted from static structures that the NNIBP lies at an important hinge region and that NNRTI-induced interference is the basis of inhibition^{35, 37}. We finally sought to link the mechanical obstruction of the hinge region with the resulting impaired catalytic function. We found that the hinge motion influences the geometry of two key regions of the active site, which lie on β -sheets on opposite sides of the NNIBP – the primer grip and the catalytic triad. As the hinge opens and closes, the separation between these groups increases and decreases, respectively. Thus, inhibition is likely to be achieved through constrained relative movements of these residues, the constellation of which is thought to be vital to catalysis^{19, 26}. We found that the “wedging” effect of nevirapine precludes full closure of the hinge motion and therefore NNRTIs may keep the primer grip and catalytic triad too distant for correct alignment of the ternary complex. Our proposal that a defective hinge distorts the polymerase active site is also supported by kinetic analyses which concluded that nucleotide incorporation is indirectly blocked by NNRTIs through a change in the conformation of the active site, as opposed to direct interference with the chemical reaction

⁵¹. We note that there may be other, longer range effects of the blocked hinge mechanism which may also contribute to inhibition of RT by NNRTIs.

Considering the magnitude of RT structural variation observed

crystallographically, a multi-copy simulation approach was adopted in this study, whereby four independent trajectories were generated for each system. In addition, the timescale of the simulations was extended to an order of magnitude greater than previous MD studies of RT, yielding a cumulative total simulation time of 360 ns. Our aim was to enhance the conformational sampling of such a large protein, on the grounds that extended and multiple trajectories increase the probability of transitions between energy minima³⁸. Indeed, significant inter-copy differences were observed in the dynamics of RT, which allowed a more complete sampling of the dominant mode of fluctuation compared to shorter and/or independent trajectories. That this motion is central to the key effect of NNRTI binding makes enhanced sampling all the more necessary for our objective. The extremely high correlation between the two most dominant motions extracted from the crystallographic and combined MD ensembles gives confidence that the multi-copy MD simulation approach can reproduce experimental structural variation.

Despite continued advances in computer hardware, conventional all-atom MD simulations of proteins are still restricted to the nanosecond timescale and are liable to becoming trapped in energy minima. Therefore, techniques have been developed to increase transitions across energy barriers and thus enhance conformational sampling, while retaining the granularity of all-atom structures. Such methods include accelerated MD⁵², replica exchange⁵³ and conformational flooding⁵⁴, and represent promising approaches for future computational studies of RT. Another possibility is the essential dynamics sampling method⁵⁵, whereby sampling is enhanced along a subset of modes extracted from existing simulations using PCA (i.e. the dominant eigenvectors). This would allow us to efficiently study the effect of a range of NNRTIs on the opening/closing motion of the p66 polymerase region, in isolation from other degrees of freedom. In particular, it could be used to predict the potency of NNRTIs and design novel compounds which optimally block the hinge region. We also note the potential of using PCA of MD ensembles for the discovery of new RT hinge regions which may also be susceptible to occlusion. Such a site on the RNH subdomain has previously been proposed³⁷ and our preliminary results suggest the existence of a viable drug binding site in this vicinity. Work is currently underway to use MD simulation to predict the mechanical impact of compounds which bind in this region, with the aim of debilitating motions necessary for the RNase activity of RT. Finally, MD simulations such as those described here can be combined with virtual docking methods to suggest leads for new drugs^{56, 57, 58}.

Methods

Simulation Systems

Two different RT crystal structures were used to generate the initial protein coordinates for the MD simulations, as shown in Figure 1. The APO1 system starts from the 2.7 Å unliganded structure of RT, which is characterized by both an occluded nucleic acid binding cleft and NNIBP (PDB code 1DLO¹⁷). The APO2 and NNB systems start from the 2.2 Å nevirapine bound structure, which has an open nucleic acid binding cleft and an open NNIBP (PDB code 1VRT⁵⁹). To generate the APO2 system, the nevirapine molecule was removed from the NNIBP (eventually to be replaced by water molecules during the solvation step). It is impossible to generate a nevirapine bound version of the APO1 system as the NNIBP does not exist and therefore there is no way to dock a drug molecule. The APO2 system was designed to assess the effect of NNRTI presence/absence on the same starting structure as the NNB system.

Simulation Setup

Missing heavy atom coordinates in PDB code 1DLO were taken from a substrate-bound structure of RT (PDB code 2HMI) after least-squares superposition and subsequent energy minimization. The same procedure was used to model missing heavy atom coordinates in PDB code 1VRT, this time using PDB code 1DLO as the template. Hydrogen atoms were added using the “pdb2gmx” procedure of the GROMACS package (<http://www.gromacs.org>). Both “repaired” protein structures contained a total 983 amino acids: residues 1–556 from the p66 subunit and residues 557–983 from the p51 subunit.

Nevirapine was parameterized for the MD force field using the PRODRG2 program, which also adds hydrogen atoms and assigns atomic partial charges⁶⁰. The assigned partial charges were validated by comparison with those calculated with the RESP module of AMBER⁶¹, which uses the electrostatic potential produced by the *ab initio* quantum chemistry package GAUSSIAN⁶² at the Hartree-Fock level with the 6–31G* basis set.

Protein structures were centered in a simulation cell of dimension 13.2 nm × 11.2 nm × 11.3 nm and energy minimized (together with nevirapine, when present) to remove unfavorable atomic contacts. The system was then solvated with explicit water molecules, energy minimized and chloride counter-ions were added to preserve electroneutrality. The solvated systems contain approximately 160,000 atoms. Final energy minimization was followed by an equilibration phase of 1 ns, during which all protein (and nevirapine, when present) heavy atoms were position restrained, to allow relaxation of the solvent around the solute. The unrestrained production runs were then simulated for 30 ns each. A total of 12 × 30 ns trajectories were generated (cumulative total simulation time of 360 ns).

All energy minimization was performed using 100 steps of the steepest descents algorithm. Equilibration was performed using harmonic restraints on all heavy atoms (force constant = 1000 kJ mol⁻¹ nm⁻²), a Berendsen thermostat⁶³, and pressure maintained at 1 bar by a Berendsen barostat⁶³. Convergence of the potential energy and volume of the system was used to ensure adequate solvent relaxation during equilibration. A separate equilibration (and subsequent production run) was performed for each of the four copies of each system, by using a different randomization seed for the initial atomic velocities³⁸. For analysis, the four 30 ns trajectories from each system were concatenated into a single 120 ns trajectory. The unrestrained production runs were performed with a Nosé-Hoover thermostat^{64, 65} and pressure maintained at 1 bar by a Parrinello-Rahman barostat⁶⁶. Simulations were run in the NPT ensemble and at a temperature of 300 K. Particle mesh Ewald (PME) was used to treat long-range electrostatics⁶⁷ and the single point charge (SPC) water model⁶⁸ was used for the solvent (as recommended for the GROMOS force field). Chloride anions were positioned randomly among the solvent to neutralize the net positive charge of the protein. An integration time step of 2 fs was used. The LINCS algorithm was used to restrain all bond lengths⁶⁹. Simulations were set up, performed and analyzed using the GROMACS v.3.3.1 molecular dynamics simulation package^{70, 71, 72}. The latest parameter set for the GROMOS force field (53A6) was used^{73, 74}. All molecular graphics were produced with VMD⁷⁵.

Principal Component Analysis

In this study, Principal Component Analysis (PCA) has been used to identify and compare the principal modes of motion of the catalytic p66 subunit of RT, using both crystallographic and MD structure ensembles. We focus on p66 as this is the subunit where polymerization and NNRTI binding takes place and is thus the most relevant region for exploring the inhibitory effects of nevirapine. Firstly, the covariance matrix is constructed, based on the 3-dimensional positional fluctuations of C α atoms from their ensemble average position (after least-squares fitting to remove overall rotational and translational motion). Next, diagonalization of the

covariance matrix yields a set of eigenvectors and corresponding eigenvalues, which represent the direction and amplitude of the motion, respectively. The eigenvectors are then ranked by decreasing eigenvalue, such that the first eigenvector represents the largest contribution to the total fluctuation of the system. In order to visualize the motions represented by the eigenvectors, the structures from the ensembles can be projected onto each eigenvector of interest and transformed back into Cartesian coordinates. The two extreme projections along the eigenvector (for example, the most open and most closed states of a “breathing” motion) can then be interpolated to create an animation (illustrated statically in this study by showing all frames simultaneously).

Principal components are compared in this study in two ways. The directions of two eigenvectors generated from different ensembles (e.g. with and without inhibitor bound) can be qualitatively compared from visual observation of the animation. Quantitatively, eigenvector directions can be compared using the inner product of two vectors, with a value of 0 indicating orthogonal directions and 1 indicating identical directions. A second approach is to compare the region sampled along common eigenvectors, by analyzing the range and distribution of ensemble projections along those eigenvectors. For example, this can be used to compare the ability of simulation ensembles to sample a motion which is obtained from an experimental dataset.

Construction and diagonalization of the covariance matrix is performed using the “g_covar” procedure of GROMACS. Projections of structures onto eigenvectors, generation of interpolation animations and calculation of inner products is performed using the “g_anaeig” procedure of GROMACS.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to acknowledge the National Center for Supercomputing Applications, the San Diego Supercomputing Center, the Center for Theoretical Biological Physics and the National Biomedical Computational Resource for computational resources and the National Science Foundation, the National Institutes of Health, and the Howard Hughes Medical Institute for financial support. We would also like to thank Eddy Arnold for valuable discussions.

References

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006;3:e442. [PubMed: 17132052]
2. De Clercq E. The design of drugs for HIV and HCV. *Nat Rev Drug Discov* 2007;6:1001–18. [PubMed: 18049474]
3. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. *Nat Med* 2003;9:867–73. [PubMed: 12835707]
4. Sarafianos SG, Marchand B, Das K, Himmel D, Parniak MA, Hughes SH, Arnold E. Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition. *J Mol Biol* 2009;385:693–713. [PubMed: 19022262]
5. De Clercq E. New developments in anti-HIV chemotherapy. *Biochim Biophys Acta* 2002;1587:258–75. [PubMed: 12084468]
6. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. *Chem Biodivers* 2004;1:44–64. [PubMed: 17191775]
7. Petit F, Fromenty B, Owen A, Estaquier J. Mitochondria are sensors for HIV drugs. *Trends Pharmacol Sci* 2005;26:258–64. [PubMed: 15860373]

8. Ren J, Stammers DK. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. *Trends Pharmacol Sci* 2005;26:4–7. [PubMed: 15629197]
9. Sarafianos SG, Das K, Hughes SH, Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. *Curr Opin Struct Biol* 2004;14:716–30. [PubMed: 15582396]
10. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, Morelli E, Novellino E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. *Curr Pharm Des* 2002;8:615–57. [PubMed: 11945162]
11. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. *Curr Opin Pharmacol* 2004;4:437–46. [PubMed: 15351347]
12. Ripamonti D, Maggiolo F. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. *Curr Opin Investig Drugs* 2008;9:899–912.
13. Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. *Expert Rev Anti Infect Ther* 2008;6:427–33. [PubMed: 18662109]
14. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. *J Med Chem* 2004;47:2550–60. [PubMed: 15115397]
15. Das, K.; Sarafianos, SG.; Arnold, E.; Hughes, SH.; William, JL.; Lane, MD. *Encyclopedia of Biological Chemistry*. Elsevier; New York: 2004. HIV-1 Reverse Transcriptase Structure; p. 388-392.
16. Lawtrakul L, Beyer A, Hannongbua S, Wolschann P. Quantitative structural rearrangement of HIV-1 reverse transcriptase on binding to non-nucleoside inhibitors. *Monatsh Chem* 2004;135:1033–1046.
17. Arnold E, Das K, Ding J, Yadav PN, Hsiou Y, Boyer PL, Hughes SH. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. *Drug Des Discov* 1996;13:29–47. [PubMed: 8874042]
18. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C, Harrison SC. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. *Proc Natl Acad Sci USA* 1995;92:1222–6. [PubMed: 7532306]
19. Ding J, Das K, Hsiou Y, Sarafianos SG, Clark AD Jr, Jacobo-Molina A, Tantillo C, Hughes SH, Arnold E. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. *J Mol Biol* 1998;284:1095–111. [PubMed: 9837729]
20. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. *Science* 1998;282:1669–75. [PubMed: 9831551]
21. Hsiou Y, Das K, Ding J, Clark AD Jr, Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH, Arnold E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. *J Mol Biol* 1998;284:313–23. [PubMed: 9813120]
22. Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, Stammers DK. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. *J Biol Chem* 2000;275:14316–20. [PubMed: 10799511]
23. Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH Jr, Kroeger Smith MB, Michejda CJ, Hughes SH, Arnold E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. *J Mol Biol* 1996;264:1085–100. [PubMed: 9000632]
24. Beyer A, Lawtrakul L, Hannongbua S, Wolschann P. Systematic investigation of non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). *Monatsh Chem* 2004;135:1047–1059.

25. Ren J, Stammers DK. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. *Virus Res* 2008;134:157–70. [PubMed: 18313784]
26. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. *Nat Struct Biol* 1995;2:303–8. [PubMed: 7540935]
27. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. *Science* 1992;256:1783–90. [PubMed: 1377403]
28. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. *Science* 1995;267:988–93. [PubMed: 7532321]
29. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. *Proc Natl Acad Sci USA* 1995;92:8046–9. [PubMed: 7544013]
30. Liu SX, Abbondanzieri EA, Rausch JW, Le Grice SFJ, Zhuang XW. Slide into Action: Dynamic Shuttling of HIV Reverse Transcriptase on Nucleic Acid Substrates. *Science* 2008;322:1092–1097. [PubMed: 19008444]
31. Madrid M, Jacobo-Molina A, Ding J, Arnold E. Major subdomain rearrangement in HIV-1 reverse transcriptase simulated by molecular dynamics. *Proteins* 1999;35:332–7. [PubMed: 10328268]
32. Madrid M, Lukin JA, Madura JD, Ding J, Arnold E. Molecular dynamics of HIV-1 reverse transcriptase indicates increased flexibility upon DNA binding. *Proteins* 2001;45:176–82. [PubMed: 11599020]
33. Shen L, Shen J, Luo X, Cheng F, Xu Y, Chen K, Arnold E, Ding J, Jiang H. Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. *Biophys J* 2003;84:3547–63. [PubMed: 12770866]
34. Zhou Z, Madrid M, Evanseck JD, Madura JD. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. *J Am Chem Soc* 2005;127:17253–60. [PubMed: 16332074]
35. Bahar I, Erman B, Jernigan RL, Atilgan AR, Covell DG. Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. *J Mol Biol* 1999;285:1023–37. [PubMed: 9887265]
36. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. *Curr HIV Res* 2004;2:323–32. [PubMed: 15544453]
37. Temiz NA, Bahar I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. *Proteins* 2002;49:61–70. [PubMed: 12211016]
38. Caves LS, Evanseck JD, Karplus M. Locally accessible conformations of proteins: multiple molecular dynamics simulations of crambin. *Protein Sci* 1998;7:649–66. [PubMed: 9541397]
39. Gorfe AA, Grant BJ, McCammon JA. Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. *Structure* 2008;16:885–96. [PubMed: 18547521]
40. van Aalten DM, Conn DA, de Groot BL, Berendsen HJ, Findlay JB, Amadei A. Protein dynamics derived from clusters of crystal structures. *Biophys J* 1997;73:2891–6. [PubMed: 9414203]
41. Amadei A, Linssen AB, Berendsen HJ. Essential dynamics of proteins. *Proteins* 1993;17:412–25. [PubMed: 8108382]
42. Mao B, Pear MR, McCammon JA, Quioco FA. Hinge-bending in L-arabinose-binding protein. The “Venus’s-flytrap” model. *J Biol Chem* 1982;257:1131–3. [PubMed: 7035444]
43. Hermann T, Heumann H. Strained template under the thumbs. How reverse transcriptase of human immunodeficiency virus type 1 moves along its template. *Eur J Biochem* 1996;242:98–103. [PubMed: 8954159]
44. Cregut D, Drin G, Liautard JP, Chiche L. Hinge-bending motions in annexins: molecular dynamics and essential dynamics of apo-annexin V and of calcium bound annexin V and I. *Protein Eng* 1998;11:891–900. [PubMed: 9862208]
45. van Aalten DM, Findlay JB, Amadei A, Berendsen HJ. Essential dynamics of the cellular retinol-binding protein—evidence for ligand-induced conformational changes. *Protein Eng* 1995;8:1129–35. [PubMed: 8819978]

46. Peters GH, van Aalten DM, Svendsen A, Bywater R. Essential dynamics of lipase binding sites: the effect of inhibitors of different chain length. *Protein Eng* 1997;10:149–58. [PubMed: 9089814]
47. de Groot BL, Hayward S, van Aalten DM, Amadei A, Berendsen HJ. Domain motions in bacteriophage T4 lysozyme: a comparison between molecular dynamics and crystallographic data. *Proteins* 1998;31:116–27. [PubMed: 9593186]
48. van Aalten DM, Amadei A, Linsen AB, Eijssink VG, Vriend G, Berendsen HJ. The essential dynamics of thermolysin: confirmation of the hinge-bending motion and comparison of simulations in vacuum and water. *Proteins* 1995;22:45–54. [PubMed: 7675786]
49. Wriggers W, Schulten K. Protein domain movements: detection of rigid domains and visualization of hinges in comparisons of atomic coordinates. *Proteins* 1997;29:1–14. [PubMed: 9294863]
50. Mukhopadhyay J, Das K, Ismail S, Koppstein D, Jang M, Hudson B, Sarafianos S, Tuske S, Patel J, Jansen R, Irshik H, Arnold E, Ebright RH. The RNA polymerase “switch region” is a target for inhibitors. *Cell* 2008;135:295–307. [PubMed: 18957204]
51. Xia Q, Radzio J, Anderson KS, Sluis-Cremer N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. *Protein Sci* 2007;16:1728–37. [PubMed: 17656585]
52. Hamelberg D, Mongan J, McCammon JA. Accelerated molecular dynamics: a promising and efficient simulation method for biomolecules. *J Chem Phys* 2004;120:11919–29. [PubMed: 15268227]
53. Sugita Y, Okamoto Y. Replica-exchange molecular dynamics method for protein folding. *Chem Phys Lett* 1999;314:141–151.
54. Grubmüller H. Predicting slow structural transitions in macromolecular systems: Conformational flooding. *Phys Rev E* 1995;52:2893.
55. Amadei A, Linsen AB, de Groot BL, van Aalten DM, Berendsen HJ. An efficient method for sampling the essential subspace of proteins. *J Biomol Struct Dyn* 1996;13:615–25. [PubMed: 8906882]
56. Amaro RE, Schnaufer A, Interthal H, Hol W, Stuart KD, McCammon JA. Discovery of drug-like inhibitors of an essential RNA-editing ligase in *Trypanosoma brucei*. *Proc Natl Acad Sci USA* 2008;105:17278–83. [PubMed: 18981420]
57. Lin JH, Perryman AL, Schames JR, McCammon JA. Computational drug design accommodating receptor flexibility: the relaxed complex scheme. *J Am Chem Soc* 2002;124:5632–3. [PubMed: 12010024]
58. Lin JH, Perryman AL, Schames JR, McCammon JA. The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme. *Biopolymers* 2003;68:47–62. [PubMed: 12579579]
59. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. *Nat Struct Biol* 1995;2:293–302. [PubMed: 7540934]
60. van Aalten DM, Bywater R, Findlay JB, Hendlich M, Hooft RW, Vriend G. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. *J Comput Aided Mol Des* 1996;10:255–62. [PubMed: 8808741]
61. Case, DA.; Darden, TA.; Cheatham, TE., III; Simmerling, CL.; Wang, J.; Duke, RE.; Luo, R.; Crowley, M.; Walker, RC.; Zhang, W.; Merz, KM.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Kolossvary, I.; Wong, KF.; Paesani, F.; Vanicek, J.; Wu, X.; Brozell, SR.; Steinbrecher, T.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Mathews, DH.; Seetin, MG.; Sagui, C.; Babin, V.; Kollman, PA. AMBER. Vol. 10. University of California; San Francisco: 2008.
62. Frisch, MJTGW.; Schlegel, HB.; Scuseria, GE.; Robb, MA.; Cheeseman, JR.; Montgomery, JA., Jr; Vreven, T.; Kudin, KN.; Burant, JC.; Millam, JM.; Iyengar, SS.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, GA.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, JE.; Hratchian, HP.; Cross, JB.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, RE.; Yazyev, O.; Austin, AJ.; Cammi, R.; Pomelli, C.; Ochterski, JW.; Ayala, PY.; Morokuma, K.; Voth, GA.; Salvador, P.; Dannenberg, JJ.; Zakrzewski, VG.; Dapprich, S.; Daniels, AD.; Strain, MC.; Farkas, O.; Malick, DK.; Rabuck, AD.; Raghavachari, K.; Foresman, JB.; Ortiz, JV.; Cui, Q.; Baboul, AG.; Clifford, S.; Cioslowski, J.; Stefanov, BB.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.;

- Martin, RL.; Fox, DJ.; Keith, T.; Al-Laham, MA.; Peng, CY.; Nanayakkara, A.; Challacombe, M.; Gill, PMW.; Johnson, B.; Chen, W.; Wong, MW.; Gonzalez, C.; Pople, JA. Gaussian 03. Gaussian, Inc; Pittsburgh, PA: 2003.
63. Berendsen HJC, Postma JPM, van Gunsteren WF, Dinola A, Haak JR. Molecular-Dynamics with Coupling to an External Bath. *J Chem Phys* 1984;81:3684–3690.
 64. Hoover WG. Canonical Dynamics - Equilibrium Phase-Space Distributions. *Phys Rev A* 1985;31:1695–1697. [PubMed: 9895674]
 65. Nose S. A Molecular-Dynamics Method for Simulations in the Canonical Ensemble. *Mol Phys* 1984;52:255–268.
 66. Parrinello M, Rahman A. Polymorphic Transitions in Single-Crystals - a New Molecular-Dynamics Method. *J Appl Phys* 1981;52:7182–7190.
 67. Darden T, York D, Pedersen L. Particle Mesh Ewald - an N. Log(N) Method for Ewald Sums in Large Systems. *J Chem Phys* 1993;98:10089–10092.
 68. Hermans J, Berendsen HJC, van Gunsteren WF, Postma JPM. A Consistent Empirical Potential for Water-Protein Interactions. *Biopolymers* 1984;23:1513–1518.
 69. Hess B, Bekker H, Berendsen HJC, Fraaije J. LINCS: A linear constraint solver for molecular simulations. *J Comput Chem* 1997;18:1463–1472.
 70. Berendsen HJC, Vanderspoel D, Vandrunen R. Gromacs - a Message-Passing Parallel Molecular-Dynamics Implementation. *Comput Phys Commun* 1995;91:43–56.
 71. Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. *J Mol Model* 2001;7:306–317.
 72. van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free 2005;26
 73. Oostenbrink C, Villa A, Mark AE, van Gunsteren WF. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. *J Comput Chem* 2004;25:1656–76. [PubMed: 15264259]
 74. Scott WRP, Hunenberger PH, Tironi IG, Mark AE, Billeter SR, Fennel J, Torda AE, Huber T, Kruger P, van Gunsteren WF. The GROMOS biomolecular simulation program package. *J Phys Chem A* 1999;103:3596–3607.
 75. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. *J Mol Graph* 1996;14:33–8. 27–8. [PubMed: 8744570]




Figure 1.

Snapshots of the three RT simulation systems under investigation. Differences in the starting conformation of the nucleic acid binding cleft and occupancy of the NNRTI binding pocket are highlighted. Four 30 ns trajectories were generated for each system. RT is shown in cartoon representation, with p66 and p51 subunits colored blue and red, respectively. A subset of water molecules are shown as VDW spheres. The binding pocket residues are shown as a molecular surface, with each residue colored uniquely. Nevirapine is shown in stick representation and colored by atom type.




Figure 2. Conformational changes of the “crystallographic ensemble” of RT x-ray structures, captured with PCA. (a) Superposition of the p66 subunits of each member of the ensemble. Protein is shown in $C\alpha$ trace representation, with each subdomain colored individually. The region referred to as the “polymerase region” is circled, composed of the fingers, palm and thumb subdomains. (b) 2D projection of each structure onto the plane defined by the top two eigenvectors from PCA of the ensemble. The ligation state of each cluster of structures is indicated, with the PDB codes as follows: APO (1DLO); Substrate bound (1RTD, 2HMI); NNRTI bound (1VRT, 2ZD1, 1HNV, 1BQM, 1VRU, 1FK9, 1EP4, 1DTQ, 1RT4, 1RT1). (c) and (d) Collective motions of the polymerase region captured by eigenvectors 1 and 2. Motions are illustrated as linear interpolations between the extreme projections of the structures onto the eigenvectors. Each cylinder therefore describes the path of each $C\alpha$ atom between the extremes (on a blue-white-red color scale). Arrows indicate the approximate direction of each subdomain.




Figure 3. Conformational drift. (a) RMSD of all $C\alpha$ atoms from the starting structure, as a function of time. Each 30 ns simulation copy is concatenated into a single 120 ns trajectory for analysis. (b) Superposition of 100 RT snapshots (taken at 1.2 ns intervals) from each simulation system. Protein is shown in $C\alpha$ trace representation, with p66 and p51 subunits colored blue and red, respectively. Attention is drawn to variations in the dynamics of the nucleic acid binding cleft.




Figure 4. Conformational flexibility. (a) RMSF of all $C\alpha$ atoms from their time-averaged positions. Each subunit is indicated by black lines, along with the subdomains of the p66 subunit (F=fingers, P=palm, T=thumb, C=connection, R=RNH). (b) Starting structures of each system, colored by RMSF on a red-green-blue color scale (scale is non-linear to clarify less mobile regions). Protein is shown in molecular surface representation ($C\alpha$ atoms only). Thumb subdomain is highlighted.




Figure 5. Essential dynamics analysis. Cumulative proportion of total variance captured by the eigenvectors from PCA of the MD ensembles. Inset shows the values for the top 5 eigenvectors, which encompass the “essential subspace”.




Figure 6.

Comparison of the motion described by eigenvector 1 from the MD and crystallographic ensembles. Motions are illustrated as linear interpolations between the extreme projections of the structures onto the eigenvectors. (a) and (b) Two alternative views of the motion, from above and behind the nucleic acid binding cleft, respectively. Arrows indicate the approximate direction of the fingers and thumb subdomains. Dotted circles highlight the nucleic acid binding cleft. The inner product (I.P.) between the eigenvector from each MD system and the crystallographic ensemble is indicated.




Figure 7.

Comparative sampling of essential motions. 2D projection of MD structures onto the plane defined by the top two eigenvectors from PCA of the crystallographic ensemble (as also shown in Figure 2). Unfilled circles represent the projections of structures taken from each MD system. Filled green circles represent projections of the crystal structures. “S1” and “S2” indicate the starting crystal structures used for the APO1 and APO2/NNB systems, respectively. The approximate range of eigenvector 1 sampled by each MD system is indicated below, along with the range sampled by the two substrate bound crystal structures.




Figure 8. Center-of-mass distance between fingers and thumb subdomains. (a) Normalized histogram of distances calculated for each MD system. (b) Distances as a function of time. Dotted lines indicate the distances for APO (PDB code 1DLO), substrate bound (PDB code 1RTD) and NNRTI bound (PDB code 1VRT) crystal structures, as references. (c) Cartoon representation of the polymerase region, illustrating the distance calculated. Fingers, thumb and palm subdomains are colored blue, red and cyan, respectively.




Figure 9. NNRTIs block a key hinge region in the polymerase region of RT. (a) Proximity of the binding pocket to the pivot points for rigid-body motion of the fingers and thumb subdomains. Residues lining the pocket are colored in orange and pivot points (calculated using HingeFind) are colored in green. Fingers and thumb subdomains (and associated regions of the palm subdomain) are colored in blue and red, respectively. Polymerase region shown in $C\alpha$ trace representation. (b) Schematic illustration of the hinge-blocking mechanism proposed for NNRTIs. NNRTIs wedge the hinge region and preclude full movement of the hinge (i.e. opening/closing of the cleft). (c) and (d) Closeup view of the hinge region. Two β -sheets line the binding pocket and slide against each other during normal function of the hinge. β -sheets are colored according to the subdomain they move in concert with. These β -sheets house the primer grip (residues Met230, Gly231) and catalytic aspartate triad (residues Asp110, Asp185, Asp186), which are shown in stick representation.